Prothena’s fair value estimate has been nudged higher from $18.33 to $20.33 per share as analysts grow more confident in the company’s partnered pipeline and its potential to drive stronger long term revenue. The model now assumes faster top line expansion, with projected revenue growth raised from 74.7% to 90.9%, reflecting optimism around milestones, royalties, and expanding indications. Read on to see how this evolving narrative is reshaping expectations for Prothena and how you can stay aligned with future updates.
Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Prothena.
🐂 Bullish Takeaways
-
Piper Sandler reaffirmed its Overweight rating and more than doubled its price target on Prothena to $36 from $15, signaling increased conviction in the stock’s upside relative to current levels.
-
The firm highlights the value of Prothena’s partnered pipeline, pointing to potential income from net sales royalties and milestone payments as a key driver of long term growth momentum.
-
Piper Sandler describes the next 12+ months as catalyst rich, indicating confidence in Prothena’s execution on upcoming milestones and its ability to sustain revenue expansion that supports the higher valuation framework.
🐻 Bearish Takeaways
-
Even as Piper Sandler turns more positive on upside potential, the reliance on future milestones and royalties underscores ongoing execution and timing risks that could challenge the durability of the current valuation if key catalysts slip or underperform.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
-
Presented new preclinical data on CYTOPE, a novel drug delivery modality for cytosolic delivery of macromolecules to the brain and periphery, at Neuroscience 2025, highlighting its potential to target previously undruggable intracellular disease pathways.
-
Reported preclinical ALS results showing that systemically administered TDP 43 CYTOPE reached the brain, localized to intracellular pTDP 43 pathology, and significantly reduced pTDP 43 aggregates and associated RNA dysregulation in mouse models and human neuronal systems.
-
Announced publication of Phase 2 data for coramitug, a potential first in class amyloid depleter antibody for ATTR cardiomyopathy, in Circulation, with the results highlighted in a late breaking session at AHA Scientific Sessions 2025 and supporting its late stage cardiovascular franchise.
-
Highlighted advancement of coramitug into the Phase 3 CLEOPATTRA trial led by Novo Nordisk, under a collaboration that could deliver up to $1.2 billion in milestones for Prothena, including additional clinical milestone payments tied to enrollment targets.